BRIEF-Alaunos Reports Preclinical Aln1003 Data Showing Effects On Insulin-Resistance-Related Biomarkers And Liver Histology In Diet-Induced Obesity Models

Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc.

TCRT

0.00

May 18 (Reuters) - Alaunos Therapeutics Inc TCRT.O:

  • ALAUNOS REPORTS PRECLINICAL ALN1003 DATA SHOWING EFFECTS ON INSULIN-RESISTANCE-RELATED BIOMARKERS AND LIVER HISTOLOGY IN DIET-INDUCED OBESITY MODELS

  • ALAUNOS THERAPEUTICS INC - ALN1003 SHOWS EFFECTS ON INSULIN-RESISTANCE BIOMARKERS AND LIVER PATHOLOGY IN PRECLINICAL STUDIES

  • ALAUNOS THERAPEUTICS INC - ALN1003-TREATED ANIMALS HAD SIGNIFICANTLY LOWER HOMA-IR SCORES AFTER BODY FAT ADJUSTMENT

  • ALAUNOS THERAPEUTICS INC - CASH RUNWAY EXTENDS INTO Q2 2026

Source text: ID:nGNX2KBR12

Further company coverage: TCRT.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.